GlassScriptPhysician profile
Cara Semino
NPI 1780294231
$2,160.32
in general payments reported to CMS, 2019-2025
8 companies · $753 in 2025
The $753 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $124 · 2022: $549 · 2023: $612 · 2024: $121 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $523.64 | 2022-2025 | Miebo, Xiidra, Revive |
| Oyster Point Pharma, INC. | $394.78 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $279.22 | 2022-2025 | Acuvue |
| Glaukos Corporation | $273.65 | 2023-2025 | Idosetr, Istent Infinite, Photrexa Viscous and Photrexa |
| Coopervision INC. | $221.90 | 2022-2025 | Myday Contact Lens |
| Sight Sciences, INC. | $209.16 | 2022-2025 | Tearcare System |
| Harrow Eye, LLC | $133.52 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Semino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.